Last updated: August 28, 2026
Furoscix is a prescription subcutaneous furosemide delivery system developed and commercialized by scPharmaceuticals Inc. The product targets patients with worsening heart failure who need rapid diuresis but may avoid hospitalization or outpatient intravenous treatment. Its commercial opportunity depends on three factors: converting hospital-based intravenous diuresis into home treatment, securing payer coverage, and reducing the cost and operational burden of recurrent heart-failure admissions.
Furoscix generated approximately $14 million to $15 million in net product revenue in 2023 and approximately $33 million in 2024, according to scPharmaceuticals' public filings and earnings disclosures. The company projected 2025 revenue of approximately $55 million to $65 million, subject to reimbursement, prescribing expansion, and patient access execution.[1][2] The product remains commercially early, with substantial operating losses and continuing dependence on capital markets.
What is Furoscix and how does the product work?
Furoscix is a single-use, on-body infusor that delivers furosemide subcutaneously over approximately five hours. It is approved for the outpatient treatment of congestion due to fluid overload in adults with chronic heart failure who require diuresis.[3]
Furoscix product characteristics
| Attribute |
Furoscix profile |
| Active ingredient |
Furosemide |
| Dosage form |
Furosemide injection delivered through an on-body infusor |
| Administration |
Subcutaneous, controlled delivery |
| FDA pathway |
505(b)(2) new drug application |
| FDA approval |
2022 |
| Commercial launch |
2023 |
| Developer and marketer |
scPharmaceuticals Inc. |
| Primary indication |
Congestion from fluid overload in chronic heart failure |
| Primary use setting |
Home or outpatient treatment |
| Main clinical alternative |
Hospital or clinic-based intravenous loop diuretic treatment |
| Core commercial proposition |
Treat selected episodes of worsening congestion without hospital admission |
The system is designed to produce exposure comparable to intravenous furosemide while avoiding venous access. Patients generally require clinician assessment, prescription authorization, training, and monitoring. This limits Furoscix's use as an unsupervised consumer product.
How large is the Furoscix market opportunity?
The addressable market is recurrent congestion in chronic heart failure, particularly among patients who experience worsening symptoms despite oral diuretic therapy. Heart failure affects millions of U.S. patients, and recurrent congestion is a leading cause of emergency visits and hospitalization.[4]
Furoscix does not compete for the entire heart-failure drug market. Its serviceable market is narrower:
- Patients who are clinically appropriate for outpatient diuresis.
- Patients whose oral diuretics are inadequate or poorly absorbed.
- Patients who have access to home nursing, specialty pharmacy, or outpatient heart-failure programs.
- Payers willing to reimburse a branded delivery system at a premium to generic furosemide.
The economic case depends on avoiding or shortening hospital stays. A single heart-failure hospitalization can cost several thousand dollars, and recurrent admissions create material costs for Medicare Advantage plans, accountable-care organizations, and integrated delivery networks.[5] Furoscix must demonstrate that its acquisition and administration cost is lower than the expected cost of hospitalization, emergency treatment, or clinic-based intravenous diuresis.
Which patients are most commercially attractive?
The most attractive initial segments are patients with:
- Recurrent heart-failure admissions.
- Poor response to oral loop diuretics.
- Difficulty absorbing oral medication because of gut edema.
- Reliable caregiver or home-health support.
- Established relationships with advanced heart-failure clinics.
- Coverage through payers with incentives to reduce admissions.
The product is less attractive for patients with severe instability, hypotension, advanced renal failure, limited home support, or a need for immediate inpatient evaluation.
What is the financial trajectory for Furoscix?
Furoscix revenue has increased from a launch-stage base, but scPharmaceuticals remains loss-making because sales, market access, manufacturing, patient services, and commercial infrastructure costs are high relative to current volume.
Furoscix revenue trajectory
| Period |
Net product revenue |
Commercial status |
| 2022 |
Minimal or pre-commercial revenue |
FDA approval year |
| 2023 |
Approximately $14 million to $15 million |
Initial commercial launch |
| 2024 |
Approximately $33 million |
Broader account and prescriber expansion |
| 2025 guidance |
Approximately $55 million to $65 million |
Company target, not reported actual revenue |
The revenue progression indicates early adoption rather than established scale. Growth of more than 100% from 2023 to 2024 reflects a low starting base, expanded payer access, and greater penetration of heart-failure programs. The next stage requires higher prescription frequency per account, improved refill persistence, and wider use outside academic medical centers.[1][2]
What is the expected path to profitability?
Profitability depends on gross-margin expansion and operating leverage. The company must absorb:
- Sales-force and account-management costs.
- Patient onboarding and reimbursement support.
- Specialty-pharmacy and distribution expenses.
- Device and cartridge manufacturing costs.
- Postmarketing, clinical, and regulatory expenses.
- Working-capital requirements associated with product inventory.
A Furoscix cartridge has materially higher revenue per treatment than generic oral furosemide, but the product also includes a disposable device and specialized delivery infrastructure. Gross margin will depend on manufacturing yield, supplier pricing, production scale, warranty costs, and reimbursement deductions.
scPharmaceuticals has historically reported significant net losses and has relied on cash, equity financing, debt, or other capital sources to fund operations.[1] Revenue growth alone will not establish profitability if commercial spending rises at the same rate as sales.
How does Furoscix compare with competing heart-failure treatments?
Furoscix competes with treatment pathways rather than with a single branded drug.
| Treatment option |
Principal advantage |
Principal limitation |
| Generic oral furosemide |
Very low cost and familiar prescribing |
Variable absorption and inadequate response in some patients |
| Generic oral torsemide |
Longer duration and potentially more predictable absorption |
Still requires oral administration and may not resolve acute congestion |
| Hospital IV furosemide |
Rapid, supervised treatment |
High facility cost and admission burden |
| Outpatient clinic IV diuresis |
Avoids full admission in selected cases |
Requires facility capacity and venous access |
| Home-health IV diuresis |
Can reduce facility use |
Requires venous access, skilled personnel, and infection controls |
| Furoscix |
Subcutaneous home delivery with no IV line |
Higher product cost, training requirements, and payer friction |
| SGLT2 inhibitors and other guideline-directed therapy |
Reduces long-term heart-failure risk |
Does not replace rapid treatment of acute fluid overload |
Furoscix's strongest competitive position is against avoidable hospital or clinic-based intravenous diuresis. Its weakest position is against inexpensive oral therapy in patients who are stable and adequately controlled.
What is the FDA regulatory status of Furoscix?
The FDA approved Furoscix in 2022 under the 505(b)(2) pathway.[3] That pathway allows reliance, in part, on existing information about a previously approved active ingredient while supporting a new formulation, route, delivery system, or clinical use.
What regulatory protections apply?
Furosemide is an old active ingredient, so Furoscix does not receive the same new-chemical-entity protection available to an entirely new molecular entity. The product's regulatory protection is more likely to derive from:
- Formulation and delivery-system patents.
- Device configuration and control-system claims.
- Method-of-use patents.
- FDA-granted exclusivity associated with the supporting clinical investigations.
- Manufacturing know-how and commercial execution.
The regulatory distinction matters because a competitor may be able to develop a different furosemide delivery system without infringing every Furoscix claim. The commercial barrier is therefore a combination of intellectual property, clinical evidence, device development, reimbursement access, and physician adoption.
What patents protect Furoscix?
Furoscix's patent estate is centered on the delivery of furosemide through a wearable or on-body system, rather than on composition-of-matter protection for furosemide itself. Public company disclosures describe issued and pending U.S. patents covering aspects of the device, delivery profile, formulation, and use in heart-failure patients.[1]
What patent claims are commercially important?
The most important claim categories are:
- On-body infusor architecture.
- Controlled subcutaneous delivery of furosemide.
- Cartridge and reservoir design.
- Delivery rates and infusion profiles.
- Formulation stability and concentration.
- Treatment of congestion outside a hospital setting.
- Methods for achieving diuresis comparable to intravenous administration.
Patent strength is moderate rather than absolute. Furosemide cannot be protected as a new molecule, and alternative wearable pumps or subcutaneous formulations may be designed around individual claims. The strongest protection is likely to come from a layered estate combining device, formulation, and method claims with manufacturing know-how.
When does Furoscix lose exclusivity?
No single date determines Furoscix's commercial exclusivity. The relevant dates include FDA regulatory exclusivity, the expiration of individual patents, pediatric extensions if applicable, and the timing of any generic or competing 505(b)(2) approval.
The product's most commercially important patent protection is expected to extend into the 2030s based on scPharmaceuticals' public intellectual-property disclosures.[1] Exact market-entry timing will depend on the Orange Book patent list, any terminal disclaimers, patent-term adjustments, Paragraph IV litigation, and the claims asserted against a challenger.
What is the Orange Book status of Furoscix?
Furoscix is an approved prescription drug product listed in FDA drug databases. Its Orange Book significance is different from that of a conventional tablet because the product combines an established active ingredient with a proprietary delivery system.[3][6]
An abbreviated new drug application challenger would need to address both drug-product requirements and the delivery-system characteristics relevant to the reference product. A competing applicant could also pursue a 505(b)(2) route for a different furosemide formulation or administration system.
What generic entry risks exist?
Generic entry risk is lower in the near term than for a simple furosemide injection, but it is not eliminated. Key risks include:
- A Paragraph IV certification against listed patents.
- A 505(b)(2) product with a different wearable delivery system.
- A conventional subcutaneous furosemide product administered by a caregiver.
- A hospital or home-health protocol that substitutes for Furoscix.
- Device or formulation patents being narrowed or invalidated.
- Regulatory approval of a product with comparable pharmacokinetics and a lower price.
A conventional generic injectable furosemide product would not necessarily replicate Furoscix's on-body delivery proposition. The more credible threat is a competing combination product that matches the outpatient use case.
Which companies are challenging Furoscix?
Through the end of 2024, no major publicly reported Paragraph IV litigation or settlement involving an approved direct generic competitor to Furoscix had become a central commercial event. The competitive threat remained developmental and strategic rather than litigation-driven.
Potential entrants include:
- Generic drug manufacturers with injectable furosemide capabilities.
- Combination-product developers with wearable pumps.
- Specialty pharmaceutical companies focused on heart failure.
- Medical-device companies with patch-pump or ambulatory infusion platforms.
- Health systems developing outpatient and home diuresis programs.
The most relevant competitive comparison is likely to involve a delivery platform, not a conventional oral generic.
What litigation and settlement risks affect Furoscix?
Publicly disclosed Furoscix litigation has not, through the end of 2024, created a clearly identified market-opening settlement comparable to major branded-drug Paragraph IV cases. The principal legal risks are prospective:
- Patent validity challenges.
- Patent-infringement litigation against a 505(b)(2) entrant.
- Product-liability claims involving skin reactions, infusion errors, or device malfunction.
- Reimbursement disputes involving medical-benefit versus pharmacy-benefit coverage.
- Manufacturing or supplier disputes affecting cartridge availability.
Any settlement with a generic or 505(b)(2) entrant could establish an authorized-entry date before full patent expiry. No material public settlement date had been established through the stated period.
How do reimbursement and market access affect Furoscix sales?
Reimbursement is the main commercial bottleneck. Furoscix is more expensive than generic furosemide, while its economic value is realized by the payer or health system that avoids a hospitalization.
Coverage can differ depending on whether the product is billed through:
- The pharmacy benefit.
- The medical benefit.
- Specialty-pharmacy distribution.
- A hospital outpatient department.
- A home-health or transitional-care program.
Prior authorization, documentation of oral-diuretic failure, and site-of-care restrictions can delay treatment. Providers also need a workflow for identifying eligible patients, obtaining the product, training the patient, and monitoring post-treatment weight, renal function, electrolytes, and symptoms.
The company's commercial model therefore depends on institutional adoption. A single cardiology practice may generate limited volume unless it is linked to a heart-failure network, payer contract, or readmission-reduction program.
What manufacturing and intellectual-property barriers protect Furoscix?
Manufacturing is a meaningful barrier because Furoscix is a combination product, not merely a prefilled furosemide syringe. Commercial production requires coordination across:
- Drug formulation and stability.
- Sterile filling.
- Cartridge or reservoir production.
- Pump and adhesive components.
- Electronics and control functions.
- Assembly and quality testing.
- Packaging and distribution.
These requirements increase development time for competitors. They also expose scPharmaceuticals to supply-chain risk. A single component shortage, device yield problem, or quality-control failure could interrupt treatment availability and damage prescriber confidence.
The barrier is durable only if the company maintains reliable supply at a cost consistent with reimbursement. Manufacturing complexity can delay competition, but it can also constrain margins.
What is the geographic coverage of Furoscix?
Furoscix is primarily a U.S. commercial opportunity. The FDA approval supports U.S. sales, while international expansion would require separate regulatory submissions, reimbursement negotiations, and distribution infrastructure.
The product's near-term value is therefore tied to:
- U.S. Medicare and Medicare Advantage access.
- Integrated health-system contracts.
- Specialty pharmacy distribution.
- Heart-failure clinic adoption.
- Regional payer policies.
- U.S. hospital readmission economics.
International expansion could improve the long-term opportunity but would require additional evidence and local market access investment.
How strong is the Furoscix patent estate and commercial position?
Furoscix has a defensible but attackable position.
Strengths
- First-mover status in wearable outpatient furosemide delivery.
- FDA approval for a defined heart-failure use.
- A product platform combining drug, device, formulation, and workflow.
- Potential savings from avoided hospital or outpatient treatment.
- Patent coverage extending beyond the launch period.
- Clinical and operational know-how that is difficult to replicate immediately.
Weaknesses
- No new-molecule exclusivity for furosemide.
- Higher cost than generic oral and injectable alternatives.
- Reimbursement complexity.
- Dependence on patient selection and clinical workflow.
- Need to prove real-world reduction in hospital utilization.
- Exposure to alternative device designs and 505(b)(2) competition.
- Limited current revenue relative to public-company operating costs.
The asset's value is driven more by market development and payer economics than by molecular patent exclusivity.
Key Takeaways
- Furoscix is an FDA-approved wearable subcutaneous furosemide system for selected adults with chronic heart-failure congestion.
- scPharmaceuticals generated approximately $14 million to $15 million in 2023 revenue and approximately $33 million in 2024 revenue.
- The company targeted approximately $55 million to $65 million in 2025 revenue, but the business remained loss-making and capital-intensive.
- The main market opportunity is avoidance of hospital or clinic-based intravenous diuresis.
- Generic oral furosemide is the primary price competitor; wearable delivery systems and 505(b)(2) products are the more relevant future patent threats.
- Furoscix relies on device, formulation, method-of-use, and manufacturing protection rather than new-chemical-entity patents.
- Payer coverage, workflow integration, and evidence of avoided admissions are more important near-term growth variables than raw heart-failure prevalence.
- Through the end of 2024, no major public Paragraph IV challenge or settlement had established an imminent generic launch.
FAQs
Is Furoscix a new drug or a new delivery system?
Furoscix uses the established active ingredient furosemide but delivers it through a proprietary on-body subcutaneous infusor. It was approved through the 505(b)(2) pathway.
Can generic furosemide replace Furoscix?
Generic oral furosemide can replace Furoscix for many stable patients, but it does not replicate controlled subcutaneous delivery for patients with poor oral response or recurrent congestion requiring outpatient diuresis.
Does Furoscix have biosimilar competition?
No. Furoscix contains furosemide, a small-molecule drug. The relevant competition is generic, 505(b)(2), combination-product, or medical-device competition rather than biosimilar competition.
What could cause Furoscix revenue to miss company forecasts?
The main risks are reimbursement denials, slow prescriber adoption, limited patient eligibility, manufacturing constraints, high patient out-of-pocket costs, and failure to demonstrate reductions in hospital utilization.
Could a competing wearable furosemide product enter before Furoscix patent expiry?
Yes. A competitor could pursue a different device, formulation, infusion profile, or 505(b)(2) regulatory strategy. Entry would depend on patent claim scope, FDA requirements, clinical evidence, and litigation outcomes.
References
-
scPharmaceuticals Inc. (2025). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2024. U.S. Securities and Exchange Commission.
-
scPharmaceuticals Inc. (2025). Fourth-quarter and full-year 2024 financial results and 2025 guidance. scPharmaceuticals investor relations.
-
U.S. Food and Drug Administration. (2022). Furoscix prescribing information. FDA.
-
Heidenreich, P. A., Bozkurt, B., Aguilar, D., et al. (2022). 2022 AHA/ACC/HFSA guideline for the management of heart failure. Circulation, 145(18), e895-e1032.
-
American Heart Association. (2024). Heart disease and stroke statistics update. American Heart Association.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.
